Source: Eur Respir J 2010; 36: 65-73
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Troosters T., Celli B., Lystig T., Kesten S., Mehra S., Tashkin D.P., Decramer M., on Behalf Of The Uplift(R) Investigators. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT(R) trial. Eur Respir J 2010; 36: 65-73

Member's Comments

No comment yet.

Related content which might interest you: Tiotropium as essential maintenance therapy in COPD Source: Eur Respir Rev 2006; 15: 51-57 Year: 2006 Subphenotyping COPD: is it relevant for therapeutic intervention and disease outcome? Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005 Impact of exacerbations in the natural course of COPD Source: Eur Respir Monogr 2013; 60: 84-95 Year: 2013 Where current pharmacological therapies fall short in COPD: symptom control is not enough Source: Eur Respir Rev 2007; 16: 98-104 Year: 2007 Resistance to resistance Source: Annual Congress 2007 - Primary care: delivering the goods: "inhaled therapies" Year: 2007 Early discharge for patients with exacerbations of COPD - a real life cohort study Source: Annual Congress 2005 - COPD - acute exacerbations Year: 2005 Can roflumilast improve clinical outcomes in moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis Source: International Congress 2016 – COPD diagnosis and management Year: 2016 A pilot study to assess the efficacy of breathlessness plans for patients with chronic obstructive pulmonary disease (COPD) Source: International Congress 2016 – COPD diagnosis and management Year: 2016 A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 217-224 Year: 2002 Impact of exacerbations on COPD Source: Eur Respir Rev 2009; 19: 113-118 Year: 2010 Roflumilast with long-acting ?2-agonists for COPD: influence of exacerbation history Source: Eur Respir J 2011; 38: 553-560 Year: 2011 Prognosis: what is the contribution of inflammation to the decline in lung function in airway disease? Source: Annual Congress 2007 - Inflammatory phenotypes in airway disease Year: 2007 The impact of treatment of chronic obstructive pulmonary disease (COPD) on functional status and quality of life of patients Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Seasonal variations in exercise tolerance, activity and quality of life in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2005 - Pulmonary rehabilitation: an evidence-based intervention Year: 2005 Correlation between pulmonary function test (PFT) parameters and quality of life (QoL) and dyspnea in stable chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2007 - Clinical aspects in COPD Year: 2007 Long-term efficacy of repeated pulmonary rehabilitation programs (PRP) in chronic airway obstruction (CAO) Source: Annual Congress 2005 - Pulmonary rehabilitation: an evidence-based intervention Year: 2005 Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations Source: Eur Respir J 2003; 21: 68-73 Year: 2003 Self-efficacy. Does it change as a result of pulmonary rehabilitation? A pilot study Source: Annual Congress 2006 - Effective strategies for chronic respiratory patient management Year: 2006 Can we predict the outcomes of treatment of patients with severe exacerbation of chronic obstructive pulmonary disease (COPD)? Source: Eur Respir J 2001; 18: Suppl. 33, 241s Year: 2001 FEV1 decline in patients with chronic obstructive pulmonary disease: Which treatment option is better for slowing of decline? Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction Year: 2015